Artivion announces presentation of late-breaking data from amds persevere trial at the 60th society of thoracic surgery annual meeting

Full ide data set demonstrates statistically significant reduction of all-cause mortality and primary major adverse events (maes) at 30 days with use of amds in acute debakey type i (adti) dissections complicated by malperfusion 72% reduction in all-cause mortality and 52% reduction in primary major maes when compared to current standard of care hemi-arch procedure atlanta , jan. 29, 2024 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of results from the amds persevere clinical trial in a late-breaking science presentation at the 60th annual meeting of the society of thoracic surgeons in san antonio, texas. the data presented analyzed clinical outcomes across the full 93 study participant ide cohort at 30-days following amds implantation.
AORT Ratings Summary
AORT Quant Ranking